Psoriasis News and Research

Latest Psoriasis News and Research

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

Anacor Pharmaceuticals announced today preliminary results from its Phase 2b trial of AN2728 for the treatment of mild-to-moderate plaque-type psoriasis.

28 Jun 2011

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.

24 Jun 2011

Disease-modifying antirheumatic drugs reduce risk of diabetes from RA, psoriasis

In a study that included nearly 14,000 patients with rheumatoid arthritis or psoriasis, the use of certain disease-modifying antirheumatic drugs was found to lower the risk of diabetes, according to a study in the June 22/29 issue of JAMA.

22 Jun 2011

Biotest, Abbott partner to develop and commercialize BT-061 for autoimmune diseases

Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis.

22 Jun 2011

Endocrine Society honors BUSM professor with The Delbert A. Fisher Research Scholar Award

Michael F. Holick, PhD, MD, director of the General Clinical Research Center and professor of medicine, physiology and biophysics at Boston University School of Medicine, is this year's recipient of The Delbert A. Fisher Research Scholar Award from the Endocrine Society for his scholarly work on the history of endocrinology.

18 Jun 2011

Healthy diet, antioxidants, critical nutrients and activities may provide the foundation to youthful living

As the baby boomer generation continues to increase in age, so does its passion to remain youthful, both inside and out. Beating the clock is now a multi-faceted, science-driven industry. From its age-old quests to find the elixir of life, to modern exploration of how microcellular activity contributes to metabolic breakdown, scientific research continues to advance its goals to enhance bodily energy, vigour and performance, and fade or stall the visible signs of aging.

16 Jun 2011

Provectus PV-10 Phase 2 trial data on metastatic melanoma to be presented at two conferences

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences.

16 Jun 2011

Magnesium essential for absorption and metabolism of vitamin D and calcium

Magnesium deficiency is an important factor in the results obtained from vitamin D. According to Dr. Carolyn Dean, MD, ND, magnesium expert and Medical Director of the nonprofit Nutritional Magnesium Association, the effectiveness and benefits of vitamin D are greatly undermined in the absence of adequate levels of magnesium in the body.

15 Jun 2011

Leukothera effectively treats psoriasis in humanized mouse xenograft transplantation model

Psoriasis is a persistent, long-lasting chronic skin disease affecting 2-3 percent of the world's population or more than 125 million individuals. For some, it is just a nuisance. For others, it is disabling.

15 Jun 2011

Humira defect lawyers file suit against Abbott Laboratories in federal court

Humira defect lawyers filed a lawsuit against Abbott Laboratories in federal court today claiming Abbott's blockbuster drug, Humira, caused a fungal infection resulting in the near-death of a Tennessee man.

14 Jun 2011

NYU Langone webinar discusses advances in the treatment of RA

Steven Abramson, MD, professor of medicine and director of the rheumatology division at NYU Langone Medical Center, hosted a webinar with colleagues from the medical center for rheumatoid arthritis community bloggers - bringing together, bench, bedside and the blogosphere to discuss advances in the investigation, care, and treatment of RA.

13 Jun 2011

OzHealth Pharma, Moberg Derma partner to distribute Emtrix in Australia and New Zealand

Moberg Derma AB has entered into a distribution agreement with OzHealth Pharma for Emtrix - for discolored and damaged nails caused by nail fungus or nail psoriasis.

8 Jun 2011

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.

8 Jun 2011

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Bristol-Myers Squibb Company today announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY (ipilimumab) prolonged the lives of patients with metastatic melanoma.

6 Jun 2011

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Bristol-Myers Squibb Company announced today it has entered in to a clinical collaboration agreement with Roche to evaluate the utility of Bristol-Myers Squibb's CTLA-4 inhibitor, YERVOY (ipilimumab), in combination with Roche's investigational oral BRAF inhibitor, vemurafenib, in treating patients with a specific type of metastatic melanoma.

4 Jun 2011

Leukemia, psoriasis drugs may treat vascular diseases

A drug that has been on the market for decades to treat leukemia and skin disorders such as acne and psoriasis may be a possible therapy for vascular diseases, including atherosclerosis and hypertension, which can lead to heart attack or stroke.

27 May 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.

27 May 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

New findings to be presented from pooled analyses of the STELARA psoriasis clinical development program showed that the safety profile of STELARA and rates of adverse events remained consistent and stable over time in adults with moderate to severe plaque psoriasis receiving up to four years of treatment.

25 May 2011

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in its Phase 2C clinical trial of PH-10 for the treatment of psoriasis. PH-10, an aqueous hydrogel formulation of Rose Bengal disodium for topical administration to the skin, is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis.

24 May 2011

Scientific evidence supports benefits of sunscreen usage to prevent skin cancer

The American Academy of Dermatology today reiterated the safety and effectiveness of sunscreens to protect against the damaging effects from exposure to ultraviolet (UV) radiation. As one component of a daily sun-protection strategy, sunscreen is an important tool in the fight against skin cancer, including melanoma, the deadliest form of skin cancer.

24 May 2011

Psoriasis News and Research

Latest Psoriasis News and Research

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Disease-modifying antirheumatic drugs reduce risk of diabetes from RA, psoriasis

Biotest, Abbott partner to develop and commercialize BT-061 for autoimmune diseases

Endocrine Society honors BUSM professor with The Delbert A. Fisher Research Scholar Award

Healthy diet, antioxidants, critical nutrients and activities may provide the foundation to youthful living

Provectus PV-10 Phase 2 trial data on metastatic melanoma to be presented at two conferences

Magnesium essential for absorption and metabolism of vitamin D and calcium

Leukothera effectively treats psoriasis in humanized mouse xenograft transplantation model

Humira defect lawyers file suit against Abbott Laboratories in federal court

NYU Langone webinar discusses advances in the treatment of RA

OzHealth Pharma, Moberg Derma partner to distribute Emtrix in Australia and New Zealand

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

Bristol-Myers Squibb's second YERVOY Phase 3 trial on metastatic melanoma meets primary endpoint

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Leukemia, psoriasis drugs may treat vascular diseases

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

New findings from STELARA psoriasis clinical trial to be presented at 22nd World Congress of Dermatology

Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of psoriasis

Scientific evidence supports benefits of sunscreen usage to prevent skin cancer

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Psoriasis News and Research

Latest Psoriasis News and Research

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in